T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Condition(s)
Leukemia
Leukemia
Age Group
0-9 years 10-17 years 18-26 years
0-9 years 10-17 years 18-26 years
Phase(s)
1
1
Drug
Cyclophosphamide based chemotherapy regimens
Genetic
Modified T cells
Trial Summary & Details
Ages: up to 26 Years
Condition: Relapsed B-Cell Acute Lymphoblastic Leukemia
Condition: Relapsed B-Cell Acute Lymphoblastic Leukemia
The purpose of this study is to test the safety of giving the patient special cells made from their own blood called “Modified T-cells”. The goal is to find a safe dose of modified T-cells for patients whose leukemia has returned to the bone marrow.